Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
Pfizer Inc PFE
News
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
Pfizer Gets FDA Approval for Expanded Use of Breast-Cancer Treatment Tukysa
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
Pfizer Declares Fourth-Quarter 2026 Dividend
Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial
Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Pfizer on Pace for Largest Percent Increase Since November 2025 — Data Talk
Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance
United States